Grace Ann Brew is an associate in Cohen Milstein’s Antitrust practice, where she represents a broad range of individuals and businesses in civil litigation, with a focus on multi-district class actions and antitrust litigation.
Prior to joining the firm, Grace Ann was an antitrust associate at a highly regarded national plaintiffs law firm.
Before entering private practice, Grace Ann was a law clerk for the Honorable Maryellen Noreika of the United States District Court for the District of Delaware.
While attending Stanford Law School, Grace Ann was an editor of the Stanford Law Review and the Stanford Journal of Civil Rights & Civil Liberties. She was also the mentorship and faculty co-chair of the Plaintiffs’ Lawyers Association.
- Pennsylvania
- Stanford Law School, J.D., 2022
- Pomona College, B.A., 2017
- Law Clerk, the Hon. Maryellen Noreika, U.S. District Court for the District of Delaware
Current Cases
Rotavirus Vaccines Antitrust Litigation
Mayor and City Council of Baltimore v. Merck Sharp & Dohme (E.D. Pa.): Cohen Milstein is representing the City of Baltimore and a putative class of third-party payors in this antitrust case alleging that Merck unlawfully monopolized the market for rotavirus vaccines using a bundled loyalty discount scheme to foreclose competition from its only competitor, GlaxoSmithKline.
Past Cases
Tracleer Antitrust Litigation
Government Employees Health Association v. Actelion Pharmaceuticals LTD (D. Md.): Cohen Milstein was court-appointed Co-Lead Class Counsel, representing the End-Payor Class in this precedent-setting and certified antitrust class action against Actelion Pharmaceuticals LTD, manufacturer of Tracleer, a life-saving pulmonary arterial hypertension medication. Plaintiffs alleged that Actelion engaged in an anticompetitive scheme to withhold samples of Tracleer from would-be rivals, in violation of FDA regulations, under the guise of the REMS program. This scheme allegedly forced self-funded employers and union health and welfare funds, as well as patients to pay supercompetitive prices and delayed less expensive generic versions of the life saving drug from entering the market. On July 1, 2026, the court granted final approval of a $65 million settlement. Parties reached the settlement two weeks before a 25-day jury trial was scheduled to commence.
Super Lawyers, Rising Star (2026)